Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00070538 · ClinicalTrials.gov registry record · Phase 1
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies
A Phase 1 study, sponsored by Vion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00070538: Completed Phase 1 study, sponsored by Vion Pharmaceuticals.
NCT00070538 is a Phase 1 study that has completed, run by Vion Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00070538, a Phase 1 study, has completed, sponsored by Vion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy, such as VNP40101M and cytarabine, use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of combining VNP40101M with cytarabine in treating patients who have hematologic malignancies, including myelodysplastic syndrome or relapsed, refractory, or untreated leukemia.
Interventions
- DRUG cytarabine
- DRUG laromustine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-06 |
| Est. Completion | 2008-01 |
| Phase | Phase 1 |
What the finished NCT00070538 record still lists
NCT00070538 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which cytarabine is the first listed.
NCT00070538 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00070538 about?
NCT00070538 is a clinical study titled "VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies". RATIONALE: Drugs used in chemotherapy, such as VNP40101M and cytarabine, use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of combining VNP40101M with cytarabi...
What is the current status of trial NCT00070538?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-06. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00070538?
The interventions under investigation include: cytarabine (DRUG), laromustine (DRUG).
Who is sponsoring clinical trial NCT00070538?
This trial is sponsored by Vion Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia